BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay.

Nearly 1 in 3 blood cancer patients and survivors say they are unlikely to get a COVID-19 vaccine, or unsure about it, despite their heightened risk

Turnkey Application Leverages Artificial Intelligence and Machine Learning Capabilities to Deliver a Comprehensive, In-Depth View of Laboratory Operations

Mednow Inc. (“ Mednow ” or the “ Company ”), Canada’s on-demand virtual pharmacy, is pleased to announce that its common shares will begin trading on the TSX Venture Exchange (“ TSXV ”) under the symbol “MNOW” effective tomorrow, March 9, 2021. This follows the Company’s successful Initial Public Offering which raised gross proceeds of $37,073,193.75.

Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference , hosted by M Vest LLC and Maxim Group LLC.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced management will participate in three upcoming virtual investor conferences: H.C. Wainwright Global Life Sciences Conference: March 9-10, 2021 33rd Annual ROTH Conference: March 15-17, 2021 Maxim Emerging Growth Conference: March 17-18, 2021

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper published in the peer-reviewed journal OncoImmunology demonstrates how belapectin, a potent galectin-3 inhibitor, in combination with an anti-OX40 (CD134) monoclonal antibody, significantly reduces tumor progression compared to either agent alone.

iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it has withdrawn its current application pursuing U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Talis One™ COVID-19 test in the CLIA moderate setting

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Japan Patent Office issued a notice of allowance for a new patent application (number 2017-543802) covering Allocetra TM